Business
Oncolytics Biotech® Inc. Announces Formation of Science and Technology Committee
Oncolytics Biotech® Inc. Announces Formation of Science and Technology Committee ...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\nOncolytics Biotech® Inc. Announces Formation of Science and Technology Committee\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntaj{\nTEXT-ALIGN: JUSTIFY\n}\n\n\n\n\n\n\nOncolytics Biotech® Inc. Announces Formation of Science and Technology Committee\nCanada NewsWire\nCALGARY, April 29, 2016\n\n\n\nCALGARY, April 29, 2016 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) (\"Oncolytics\" or the \"Company\") today announced the formation of a Science and Technology Committee made up of directors Dr. William Rice and Dr. Bernd Seizinger.\n\n\"In addition to many years of senior leadership in oncology drug development, Drs. Rice and Seizinger bring strong scientific and medical credentials along with a wealth of industry and academic contacts to their roles on the committee,\" said Wayne Pisano, Chairman of Oncolytics. \"Cancer research and drug development, and indeed our own specific understanding of how REOLYSIN® works, continue to evolve at a rapid pace. The committee is charged with supporting REOLYSIN®'s further development in the context of the broader oncology space with an ultimate focus on reaching a commercial endpoint.\"\n\nDr. William Rice has held the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013.  Preceding Aptose, he served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. He has also served as Senior Scientist and Head of the Drug Mechanism Laboratory at the National Cancer Institute-Frederick Cancer Research and Development Center, and as a faculty member in the Division of Pediatric Hematology and Oncology at Emory School of Medicine. Dr. Rice holds a PhD in biochemistry from Emory University and was a post-doctoral trainee in the Department of Internal Medicine, Division of Hematology and Oncology at the University of Michigan Medical Center.\n\nBernd Seizinger, MD, PhD, has held the position of Chairma...